RNA, U6 small nuclear 858, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-858P profile across patient tissues and cancer cell-line models. RNU6-858P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU6-858P is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, RNU6-858P RNA expression shows 7,010 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, HNSC, and KIRP as cancer lineages where RNU6-858P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-858P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-858P survival associations across molecular data types. RNU6-858P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-858P RNA expression–survival associations across cancer types. High RNU6-858P expression shows unfavorable associations in KIRC, MESO, LIHC, LUAD and TGCT, but favorable associations in ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU6-858P RNA expression.
This table summarizes RNU6-858P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-858P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-858P shows lower tumor expression in UCEC and higher tumor expression in HNSC, READ and PRAD. The HNSC box plot shows higher RNU6-858P RNA expression in tumor versus normal tissue (log2 FC = +0.178, t-test p = .021).
This table shows molecular features associated with RNU6-858P in patient tissues and cancer cell lines. In patient samples, RNU6-858P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
